Agilent Technologies is launching Agilent Advanced Therapeutics, a unified CDMO solution integrating expanding capabilities across Canada and the United States.

To begin, Agilent Advanced Therapeutics’ CDMO portfolio encompasses oligonucleotides, microbial fermentation, both complex and synthetic chemistry, and bioreagents. Also included: highly potent active pharmaceutical ingredients, and cell line development.

Bringing US and Canada Together

Agilent says the new arrangement ties together the strengths of BIOVECTRA, in Canada, and Nucleic Acid Solutions, located in Colorado. In doing so, the company is able to offer a full suite of premium scalable and customizable manufacturing solutions.

In November 2025, BIOVECTRA and Revolution Biomanufacturing announced a collaboration to optimize untranslated regions and codon usage, enhancing mRNA stability.

Agilent in the CDMO Space

Meanwhile, having an integrated platform gives customers streamlined access to end-to-end development and manufacturing services—with a single partner. As Agilent President and CEO Padraig McDonnell elaborates, the platform spans discovery and process development, to clinical or commercial-scale manufacturing.

“[It] strengthens our ability to support our customers and reinforces our long-term commitment to growth, investment, and leadership,” McDonnell said. “[It’s] a more integrated experience, deeper technical partnership, and a trusted team that understands what it takes” to deliver therapies.

Simon May, president of Agilent’s Life Sciences and Diagnostics Markets Group, agreed.

“This … reflects the combined excellence of our teams and our commitment to advancing the next generation of therapies,” May said. “We are excited to bring our unified Agilent Advanced Therapeutics capabilities to partners around the world.”

Agilent Technologies reported generating $6.95 billion in revenue in fiscal year 2025. The company, headquartered in Santa Clara, Calif., employs approximately 18,000 people worldwide.